For two decades, the world’s biggest drugmakers tried to silence a single inflammatory receptor in the lungs and failed. Now, an Australian biotech company thinks it has found a solution.
This story features in Issue 24 – out now. Tap here to secure your copy.
You can’t breathe; you basically drown”, that’s how Siro Perez, chief executive officer of Atisama Therapeutics, describes what advanced chronic obstructive pulmonary disease (COPD) feels like.
